AzTrials
AzTrials

Lung CancerNCT06514248

Clinical Evaluation of the V5-LU01 AI Software in Thoracic CT for V5med Inc.

A study testing V5med Lung AI in people with Lung Cancer, run by V5med Inc. at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

STUDY DESIGN: This is a two-arm retrospective, multi-reader, multi-case, (MRMC) randomized reader study. OBJECTIVE: Primary: The primary objective of this clinical study is to prove that radiologist's performance aided with V5med Lung AI is superior to the unaided for detecting qualified lung nodules. Read more about this study

Who is it for?
Ages 55 to 77 years
Conditions the study is for
Lung Cancer
What is being tested?
V5med Lung AI
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
16 participants
Where
1 siteUnited States
Study dates
18 Dec 2023to 17 May 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 55 to 77 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Screening chest CT taken of asymptomatic patients age 55 - 77 with history of smoking
  • Non-screening chest CT of an adult (age 18 and older) without comorbidity
  • Primary Lung Cancer, Biopsy-proven with radiology report
  • <= 2.5mm slice spacing, no gaps
  • Standard reconstruction kernels
  • Maximum of 7 lung nodules per CT scan
  • Nodules must be 4-30mm in size (though majority of them will be 20mm or smaller)

Who cannot join

  • Acute pneumothorax
  • Incomplete inclusion of both lungs, within the field of view, including both Apices
  • Excessive motion artifacts or beam-hardening artifacts
  • Symptomatic patients with co-morbidities

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Arlington Innovation Center: Health Research

    Arlington, Virginia, 22203

Other trials in United States

About this study

Official title: Evaluation of V5 Lung AI Software With A Two-Arm Comparative Reader Study

STUDY DESIGN:

This is a two-arm retrospective, multi-reader, multi-case, (MRMC) randomized reader study.

Read more

OBJECTIVE:

Primary: The primary objective of this clinical study is to prove that radiologist's performance aided with V5med Lung AI is superior to the unaided for detecting qualified lung nodules.

Secondary: The secondary objective of this clinical study is to prove that the radiologist's reading time is not significantly increased when aided with V5med Lung AI.

Addition Objectives: To prove that the agreement (e.g., in kappa correlation coefficient) between experts and radiologist's Lung-RADS score aided with V5med Lung AI is superior to the unaided.

NUMBER OF SUBJECTS:

Retrospective CT studies from approximately 350 patients will be included in the study with approximately 170 true positive cases and 180 normal cases.

PRIMARY ENDPOINTS:

Scores given by the radiologists with and without V5med Lung AI will be recorded and compared to the true status of the study-cases. The frequency of the scores for each method (Aided, Unaided) will be tabulated and LROC curves constructed along with sensitivity, specificity, PPV, NPV and clinical actions. Additionally, machine nodule detection rate and false positives per patient on normal cases will be measured.

PATIENT POPULATION:

The study will target approximately two hundred (200) patients whose CT lung nodules were shown to be cancer and one hundred and eighty (150) patients who have no lung nodule greater than 4mm. The patient population will be consistent with the national lung cancer screening protocols.

Read the detailed description

Overview of the Study:

A reader study with sixteen participating radiologists will be conducted. A location-specific receiver operating characteristic (LROC) curve will be used to evaluate radiologists' detection performance in detecting qualified lung nodules on chest CT scans with and without the use of the V5med Lung AI system. The reading time for each case will also be recorded.

The 16 study radiologists will be split into two groups, X and Y. The 350 chest CT scans will be split into two subsets, A and B. Group X radiologists will interpret subset A without AI and subset B with V5med Lung AI. Group Y radiologist will interpret subset B without AI and subset A with AI. After a minimum of one month, each radiologist group will interpret the same images again but in the reverse order with regard to study modes (without AI and with AI). Please see Figures 1 and 2 for detailed arrangement of the radiologist interpretation sessions.

During the baseline reading session the radiologist will mark each location of qualified nodules and assign a score. If at least one suspicious nodule is observed, the radiologist will also indicate a Lung-RADS score (i.e., 2, 3, 4A, 4B, or 4X) at the end of case interpretation.

During the second reading (i.e., aided reading) session, the radiologist will be presented with a chest CT with CADe marks displayed on the "left window" and the same chest CT without CADe marks displayed on the "right window". If the radiologist confirms a nodule, the radiologist will mark the location on the chest CT displayed on the right window. This may or may not correspond to the locations of the CADe marks as displayed on the left window. The same as in the baseline study, the radiologist will assign a score (level of suspicion) to each suspicious location and provide a Lung-RADS score for the chest CT case, if at least one location on the CT is marked.

Based on the suspicious locations and their scores (level of suspicion) assessed by study radiologists, LROC curves can be constructed for both the baseline and the aided reads, and the significance of any difference will be calculated. The LOS score will also be used to calculate sensitivity, specificity, PPV and NPV.

Number and types of Chest CT cases:

Retrospective chest CT image series from approximately 350 cases will be included in the study. Approximately two hundred (200) cases will have at least one nodule size greater than 4mm. These cases will have radiology-prove report and/or biopsy-confirmed cancers. Also included as nodule images are those where a nodule was not detected at that time, but was detected and acted on based on a subsequent CT. These are the prior images where the nodule can be identified in the same location as on the "current" image confirmed by the radiologist expert panel (using a majority of three as the decision criterion). In addition, approximately one hundred and fifty (150) cases will not have a nodule size greater than 4mm.

The selected chest CT cases for the 2-arm comparative reader study, randomly selected from a larger pool of CT cases, will be enriched in the following way:

  1. Lung nodules (cancers and benign nodules) will be nodule size ranging from 4mm to 30 mm. The proportion of nodules 20 mm or less may take majority of the cases with nodule(s) since this lung lesion size range is where we expect the major impact of this software to be.
  2. Non-Solid (ground glass) nodules will be added to the study dataset (based on availability) to determine the performance of the system on non-solid nodules. For this group, to have sufficient cases, we may include more benign (non-malignant) non-solid nodules.
  3. In this project, VIRGINIA TECH study team will perform a machine standalone test of the V5med Lung AI algorithm followed by a reader performance evaluation study. V5med Technologies will provide a system configured with the operating point set to be used for the reader studies and a configuration for an "open" system to be used for machine testing and to generate free-response ROC (FROC) curve.

The Design of Two-Arm Comparative Study:

The First Arm Study:

Perform a baseline reader study without any special tool. The reader is asked to mark all potential nodules not less than 4mm. For each mark, the size of region of interest (ROI), reader score (level of suspicion), and time spent will be recorded for the statistical analyses.

The Second Arm Study:

Perform another reader study using the V5med Lung AI as the aided read. The reader is asked to mark all potential nodules not less than 4mm assisted by V5med Lung AI. Some or majority of ROIs' parameters will be pre-filled by V5med Lung AI. The reader will make final determination for each location. The marked location, LOS score, Lung-RADS score, and time spent will be recorded for the statistical analyses and compared to the first arm study.

The primary study hypothesis is that the detection of lung nodules with the use of V5med Lung AI and associated functions is superior to the detection of lung nodules without the use of V5med Lung AI, as measured by the area under the LROC curve.

Conditions
Lung Cancer
Being tested
V5med Lung AI
Medical subject headings
Lung Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • V5med Lung AIDevice

    During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed on the "left window" and the same original without any AI mark with be display on the "right window". Deeming a nodule, the radiologist will mark location. These may or may not correspond to the locations of the CADe markers. As in the baseline study, the radiologist will assign a level of suspicious to each mark and provide a Lung-RADS score and the size of longest dimension.

Study groups in NCT06514248
Study groupRoleWhat they receive
Reader Study without AI (Baseline )No interventionDuring the baseline reading session the radiologist will mark each location of qualified nodules and assign a score. If at least one suspicious nodule is observed, the radiologist will also indicate a Lung-RADS score (i.e., 2, 3, 4A, 4B, or 4X) at the end of case interpretation.
Reader Study with AI (Aided by V5med Lung AI)Active comparatorPerform another reader study using the V5med Lung AI as the aided read. The reader is asked to mark all potential nodules not less than 4mm assisted by V5med Lung AI. Some or majority of ROIs' parameters will be pre-filled by V5med Lung AI. The reader will make final determination for each location. The marked location, LOS score, Lung-RADS score, and time spent will be recorded for the statistical analyses and compared to the first arm study.
Receives: Device: V5med Lung AI

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparing the Detection Accuracy, Sensitivity, and Specificity of Clinically Actionable Lung Nodules

    The detection rates in accuracy, sensitivity, and specificity on clinically actionable lung nodules were computed and compared for Aim 1 (baseline) and Arm 2 (study participants were aided with V5med Lung AI) studies.

    Measured: 6 months

  2. Comparing LROC Curve in the Detection of Clinically Actionable Lung Nodules Among Normal

    The areas under location-specific Receiver Operating Characteristic (LROC) curves were computed and compared for Aim 1 (baseline) and Aim 2 (study participants were aided with V5med Lung AI).

    Measured: 6 months

Secondary outcomes (1)
  1. Average Reading Time Per Case

    The average reading times per reader per case were computed and comapred in both Aim 1 and Arm 2 (study participants were aided with ClearRead CT software) studies.

    Measured: 4 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jul 2024
  2. Study start18 Dec 2023
  3. Primary completion17 May 2024
  4. Study completion17 May 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
16 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06514248
Sponsor's protocol ID
23-806
Status last verified
Jul 2024
First submitted
5 Jul 2024
Last updated
23 Jul 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing V5med Lung AI in people with Lung Cancer, run by V5med Inc. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Comparing the Detection Accuracy, Sensitivity, and Specificity of Clinically Actionable Lung Nodules (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in